Browsing: Commentary
Guest commentary articles from industry experts from across the longevity and mortality markets. If you would like to submit an article for consideration for publishing by Longevity and Mortality Investor, please click here.
The International Capital Standard (ICS) introduces a new approach to discounting illiquid liabilities — one that includes an explicit credit risk premium. But how does it compare to Solvency II’s Fundamental Spread? And what might it mean for UK insurers already familiar with the Matching Adjustment?
As our population ages, the significance and frequency of falls increases. This affects life expectancy as well as morbidity and mortality.
Many firms maintain a longevity risk capital model, making sure the methodology remains relevant and proportionate to the risk. We shine a spotlight on these models here, considering how they may evolve with post-pandemic data and Solvency II reforms.
The third of our reviews of the Life Insurers Fact Book 2024 focusses on how factors that could impact the life settlement market are developing. Key amongst these are the surrender volumes, which help indicate the volumes of policies that could be available to trade, and the rate of new life insurance business which will provide the fuel for the market in future
The UK’s bulk purchase annuity market is now firmly established as a £50bn a year market.
The outlook for metastatic melanoma continues to improve, driven by advancements in therapeutic strategies and ongoing research.
As was the case last year, the overall message here is one of consistency. As counterparties for longevity and mortality risk investors, US life insurers remain strong.
An insurance buy-out is not the only option in town for UK defined benefit pension schemes looking to de-risk – but is it still the best one?
The Life Insurance Settlement Association (LISA) is refining its mission and vision for the future and to develop an actionable plan to achieve those goals.
Arguably, the US life insurance industry had a strong 2023 from a balance sheet perspective. Asset growth outpaced liability growth, and policy reserves grew as well and the legacy of the Covid-19 pandemic would appear to be diminishing.